









Markets
/
Stocks
/
nasdaq-ztek
/

Zentek Ltd

ZTEK

0.937USD

+0.004+0.42%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

98.08MMarket Cap

LossP/E TTM



Zentek Ltd

0.937

+0.004+0.42%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

247 / 506

Overall Ranking

403 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Zentek Ltd. is an intellectual property technology company. The Company is focused primarily on commercializing ZenGUARD, as well as on the development of certain aptamer technologies and other nanomaterials-based technologies. Its patented technology platform, ZenGUARD, is shown to have enhanced viral filtration efficiency for surgical masks and heating, ventilation, and air conditioning (HVAC) systems. The Company is also focused on the research, development and commercialization of novel products, seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. The Company has installed industrial-scale production equipment to produce the ZenGUARD coating formulation at its York Rd., Guelph, Ontario location, which is permitted for industrial use. It is also working on developing processes to synthesize graphene, GO and graphene quantum dots, along with other possible applications for graphene-based materials.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1024.99% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 606.45K.

Fairly Valued

The company’s latest PE is -10.99, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.92M shares, decreasing 1.20% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 10.65.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.28, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 42.48K, representing a year-over-year increase of 958.38%, while its net profit experienced a year-over-year increase of 46.37%.

Score

Industry at a Glance

Previous score

6.28

Change



Financials

6.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.80

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.41

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.14

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -10.92, which is -15.87% below the recent high of -9.19 and -1.51% above the recent low of -11.09.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 247/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.46, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.24 and the support level at 0.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.46

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(5)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.031

Buy

RSI(14)

55.548

Neutral

STOCH(KDJ)(9,3,3)

46.680

Neutral

ATR(14)

0.128

Low Volatility

CCI(14)

18.166

Neutral

Williams %R

51.582

Neutral

TRIX(12,20)

0.857

Buy

StochRSI(14)

20.237

Neutral

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.939

Sell

MA10

0.937

Sell

MA20

0.841

Buy

MA50

0.853

Buy

MA100

1.151

Sell

MA200

1.105

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fenton (Gregory)

3.14M

+1.25%

Dube (Francis Jacques)

1.14M

+26.81%

Scotia Capital Inc.

901.24K

-6.00%

Van der Kuur (Colin Stuart)

571.33K

Wallman (Eric)

475.97K

Wood (Peter)

237.72K

Shacklock (Ryan)

178.20K

Desjardins Securities Inc.

147.18K

-2.00%

CIBC World Markets Inc.

124.25K

-2.89%

RBC Dominion Securities, Inc.

88.75K

+5.65%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.